Fly News Breaks for February 25, 2020
Feb 25, 2020 | 08:08 EDT
As previously reported, Jefferies analyst Biren Amin upgraded Regeneron (REGN) to Buy from Hold with a price target of $492, up from $355, after reports in an FDA database showed an elevated rate of vasculitis in patients treated with Novartis' (NVS) Beovu compared to Regeneron's Eylea. Two retina doctors he spoke to expect Beovu use to significantly decrease in the near-term, noted Amin, who raised his Eylea estimates to be ahead of consensus by $180M in 2020 and $450M in 2021 and 2022, respectively.
News For REGN;NVS From the Last 2 Days
Apr 12, 2021 | 09:28 EDT
Benchmark analyst Aydin Huseynov expects full FDA approval of Regeneron's (REGN) REGEN-COV could be coming within weeks, possibly in both 2.4g and 1.2g doses, citing the 70% reduction in risk of hospitalization or death in a 4,600-patient REGEN-COV randomized placebo-controlled trial in non-hospitalized COVID-19 patients as well as what he sees as "an apparent preference" for Regeneron's cocktail over Eli Lilly's (LLY). Huseynov has a Buy rating and $590 price target on Regeneron shares.